Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome(EARLY ACS) - EARLY ACS

Schering-Plough A/S0 个研究点目标入组 10,500 人开始时间: 2005年8月23日最近更新: 2012年5月1日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Schering-Plough A/S
入组人数: 10,500

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. 18 years of age or older.
•2. Willing and able to give informed consent. The patient must be able to comply with study procedures and follow-up through 1 year
•3. Experiencing symptoms of cardiac ischemia at rest (angina or anginal equivalent) with episode(s) lasting at least 10 minutes within 24 hours of randomization and have at least 2 of the following:
•- Electrocardiogram (ECG) changes: •New or presumable new ST-segment depression > or =0.1 mV or transient (<30minutes) ST-segment elevation > or = 0.1mV in at least 2 contiguous leads
•- Elevated troponin I or T greater than the established criteria at site or creatine kinase-MB fraction (CK-MB) greater than the site's upper limit of normal (ULN)
•- 60 years of age or older.
•Or have all 3 of the following:
•- Prior history of Cardiovascular disease (eg. prior MI, PCI, CABG, > 50% coronary artery stenosis by angiography, ischemia present on exercise-stress imaging or pharmacologic-stress imaging study, peripheral vascular disease (PVD) with symptoms and objective evidence (eg. ankle brachial index (ABI)>or = 0.9, non-hemorrhagic cerebrovascular accident (CVA).
•- Elevated cardiac troponin I or T greater than the established criteria at each site or CK-MB greater than the site´s ULN
•- 50-59 years of age
•4. Able to be randomized within 12 hr of presentation
•5. Plan to undergo an invasive strategy after receiving study drug for 12 to 96 hrs
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Pregnancy-known or suspected-premenopausal females must have a confirmed negative urine or serum pregnancy test before study enrollment
•2. Renal dialysis within 30 days prior to randomization
•3. Other serious illness (eg, active cancer within 5 years, sepsis) or any condition that the investigator feels would pose a significiant hazard to the patient if the investigational therapy was to be initiated.
•4. History of a hemorrhagic stroke at any time or non-hemorrhagic stroke of any etiology within 7 days; central nervous system structural damage (eg, neoplasm, aneurysm, intracranial surgery);any recent severe head or facial trauma.
•5. History of a bleeding diathesis, including documented gastrointestinal (GI) bleeding or any history of clinically significant GI bleeding, or evidence of active abnormal bleeding within 30 days prior to randomization or an international normalized ratio (INR) >1.8 due to treatment with an oral anticoagulant or underlying coagulopathy.
•6. Major surgery, biopsy of a parenchymal organ, or significant trauma within 14 days prior to randomization
•7. History of heparin or eptifibatide induced thrombocytopenia or a platelet count of <100,000 mm3. Platelet count should be confirmed by drawing a second blood sample.
•8. Intent to use a direct prothrombin inhibitor, factor Xa inhibitor, low molecular weight heparin other than enoxaparin, or any other anticoagulant other than UFH or enoxaparin (ADDED 03/Jun/05 - or bivalirudin). (Exception: warfarin after completion of study drug infusion is permitted in patients with an indication for oral anticoagulation.
•9. Recent therapy with a GP IIB/IIIa inhibitor; abciximab within 24 hours prior to randomization, or eptifibatide, tirofiban, or other agent within 4 hours prior to randomization.
•10 Known hypersensitivity to any component of the products evaluated in the study.

研究者

发起方

Schering-Plough A/S

相似试验

进行中（未招募）

不适用

Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome(EARLY ACS) - EARLY ACSPatients who present with high-risk non-ST-segment elevation acute coronary syndrome who are planned to undergo an invasive strategy no sooner than the next calendar day following randomization.MedDRA version: 9.1Level: LLTClassification code 10051592Term: Acute coronary syndrome

EUCTR2004-000120-32-CZSchering-Plough Research Institute9,500

进行中（未招募）

1 期

Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS) - EARLY ACSPatients who present with high-risk non-ST-segment elevation acute coronary syndrome who are planned to undergo an invasive strategy no sooner than the next calendar day following randomization.MedDRA version: 6.0 Level: PT Classification code 10051592

EUCTR2004-000120-32-GBSchering-Plough Research Institute10,500

进行中（未招募）

不适用

EUCTR2004-000120-32-HUSchering-Plough Research Institute10,500

进行中（未招募）

不适用

EUCTR2004-000120-32-ATSchering-Plough Research Institute10,500

进行中（未招募）

1 期

EUCTR2004-000120-32-BESchering-Plough Research Institute10,500